Branded Generics Market to Double Revenue by 2031

 

ESOMAR-certified consulting firm Future Market Insights (FMI) in its latest report forecasts that the global branded generics market will register healthy growth at a CAGR of 5.8% between 2021 and 2031. The swift growth of branded generics market can be attributed to the growing number of patent expiry of branded or blockbuster drugs along with increasing prevalence of chronic diseases. Rising demand for cheap medical treatments is positively impacting the demand in the market.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1260

Branded generics are pharmaceutical drugs that have been re-released with a different brand name. They are used to treat various diseases such as diabetes, hypertension, back pain and others. These drugs occupy small but lucrative subset of the entire generic market

Since branded generics are free from patenting, companies are investing handsome amounts on this drug category. The market is set to reach a valuation of around 283.2 Bn in 2021, with top players in tier-1 accounting for 20%-25% market share.

The entry of new players, simple market authorization procedures, greater profit margin and off-invoice discounts will expand branded generics market during the forecast period.

As per the FMI’s analysis, despite the slight setback due to the pandemic, the global branded generics market registered year-on-year (Y-o-Y) growth at 4.9% CAGR during 2020-2021.

“Rising demand for branded generics across both developing and developed economies along with high penetration of pharmaceutical industry will offer lucrative growth opportunities for the branded generics manufacturers during the forecast period” says the FMI analyst.

For Information On The Research Approach Used In The Report, Request TOC@ https://www.futuremarketinsights.com/toc/rep-gb-1260

 

Key Takeaways from FMI’s Branded Generics Market Study

• China and India are spearheading the growth of Asia Pacific market spurred by the increasing adoption of branded generics by large-scale pharmacy chains in the emerging economies
• The U.S. will lead the North America’s branded generics market, registering a growth at 3.83% CAGR during the forecast period.
• The market in India is expected to offer lucrative growth opportunities to branded generics manufacturers backed the expansion of pharmaceutical industry
• In terms of therapeutic application, cardiovascular diseases and diabetes are expected to account for considerable market share
• Oral solid dose pharmaceutical formulation continues to be highly preferred among patients. The oral segment accounts for over 55% share of the global branded generics market.

Competitive Landscape

Teva, Abbott Laboratories, Novartis, Mylan, Pfizer are some prominent players operating in the branded generics market cumulatively hold around 20-25% market share.

Key players operating in branded generic market are focusing on expanding their business in emerging markets. They are adopting various organic and inorganic growth strategies such as mergers and acquisitions, advanced product development and collaborations to gain a competitive edge in the market.

• In October 2020, Glenmark Pharmaceuticals, introduces NINDANIB (Nintedanib) for the treatment of pulmonary fibrosis in India. Glenmark has been amongst the first to launch the branded generic version at an affordable cost for the treatment of pulmonary fibrosis in India.

 

Ask from the Market Research Expert @ https://www.futuremarketinsights.com/askus/rep-gb-1260

More Valuable Insights on Branded Generics Market

In its latest report, FMI provides an incisive coverage on the global branded generics market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031.The study provides compelling insights on branded generics market on the basis of therapeutic application (oncology, cardiovascular diseases, diabetes, neurology, gastro intestinal diseases, dermatology diseases, analgesic and others), drug class (alkylating agents, anti-metabolites, hormones, anti-hypertensives, lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptics and others ), formulation type (oral, parenteral, topical, others) and distribution channel (hospital pharmacies, retail pharmacies, online pharmacies, drug stores) across seven major regions.

About the Healthcare Division at Future Market Insights

Future Market Insights facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business. Know more about our sector coverage here

Explore FMI’s Extensive Coverage on Healthcare Domain 

Dialysis Equipment Market The global Dialysis Equipment Market size is projected to reach US$ 17.87 Bn in 2022, finds Future Market Insights (FMI) in a recent market study. 

Gait Trainer Market  The global Gait Trainer Market is predicted to exhibit progression at a modest CAGR of 4.9% over the forecast period. The market is set to hold a net worth of US$ 342.7 Mn in 2022

Appendage Management Market The global Appendage management Market is estimated to expand from a value of US$ 223.9 Mn in 2021, to a value of US$ 352.5 Mn by 2028 end, and growing at a CAGR of 6.6% during the forecast period.

About Future Market Insights (FMI) 

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. 

 

Contact: 

Future Market Insights, 

1602-6 Jumeirah Bay X2 Tower, 

Plot No: JLT-PH2-X2A, 

Jumeirah Lakes Towers, Dubai, 

United Arab Emirates 

For Sales Enquiries: sales@futuremarketinsights.com 

For Media Enquiries: press@futuremarketinsights.com

Website: https://www.futuremarketinsights.com/ 

Report: https://www.futuremarketinsights.com/reports/branded-generics-market
Press Release Source https://www.futuremarketinsights.com/press-release/branded-generics-market